Stem cells show promise – but they also have a darker side
By Jill Johnson,
The Conversation
| 05. 25. 2017
Everyone seems to be excited about stem cells. Their excellent promise as a treatment for a range of diseases and injuries mean almost guaranteed coverage for research. While some types of stem cells are already being used in treatment – for treating diseases of the blood and leukaemia, for example, multiple sclerosis and problems in the bone, skin and eye – there’s still a lot of hype and exaggeration, with some even selling empty promises to seriously ill or injured patients.
There are many different types of stem cells in the body and they have varying abilities. When most people think of stem cells, it’s often of embryonic stem cells, which have been controversial for ethical reasons, or their closely related cousins, induced pluripotent stem (iPS) cells, adult cells that have been reprogrammed to acquire stem cell-like properties. As the word “pluripotent” suggests, these stem cells have the capacity to transform into any cell type in the body, with the exception of egg and sperm cells.
There are other types of stem cells, however, that are considered...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...